Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 152Breast Neoplasms 40Prostatic Neoplasms 31Insulin Resistance 30Obesity 23Neoplasms 16Endometrial Neoplasms 15Pancreatic Neoplasms 14Infertility 14Colorectal Neoplasms 13Carcinoma, Non-Small-Cell Lung 12Anovulation 10Lung Neoplasms 9Neoplasm Metastasis 8Hyperandrogenism 8Glioblastoma 8Diabetes Mellitus 8Squamous Cell Carcinoma of Head and Neck 7Metabolic Syndrome 7Melanoma 7Rectal Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Head and Neck Neoplasms 5Diabetes Mellitus, Type 2 5Brain Neoplasms 5Adenocarcinoma 5Weight Loss 4Uterine Cervical Neoplasms 4

Interventions

Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Progression-Free Survival × Metformin × Clear all
NCT06826092 2025-02-13

Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy

Kaohsiung Medical University Chung-Ho Memorial Hospital

Phase 2 Recruiting
110 enrolled

Progression-Free Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡